RLDatix Life Sciences Resources
Manager Enablement: The Missing Link in Performance
Better reps start with better coaches. Life sciences organizations might invest heavily in product training, market access strategy, and sales execution. Still, one critical lever for performance often gets less attention: the people leading the field teams. Managers are the connective tissue between corporate strategy and… Read More
PHS Pricing Under Pressure: Managing Duplicate Discounts and Diversion Risks in 2025
Duplicate discounts and diversion are two of the most persistent risks in pharmaceutical pricing, and in 2025, they’re under the microscope. HRSA audits are tougher, state-level carve-in/carve-out rules are more complex, and manufacturers are expected to prove not only that they have controls in place, but that those controls are… Read More
HRSA Launches 340B Rebate Model Pilot Program: What Manufacturers Need to Know
The Health Resources and Services Administration (HRSA) has introduced a significant new development for the 340B Drug Pricing Program with the launch of its 340B Rebate Model Pilot Program. This initiative offers drug manufacturers a fresh, alternative pathway to comply with their 340B pricing obligations, aimed at addressing longstanding industry… Read More
Modernizing Customer Class of Trade Management: Best Practices for Clean Segmentation & Contracting
If your Class of Trade (COT) data isn’t clean, your entire revenue management process is at risk. From chargebacks to government pricing, every downstream calculation depends on getting COT right. And in today’s marketplace, the margin for error is shrinking fast. With IDNs, specialty… Read More
What It Takes to Launch in 2025: MFN, MFP, IRA, and the New Rules of the Road
Launching a drug in today’s market is all about navigating the right path. With Most Favored Nation (MFN) policies under discussion, Maximum Fair Price (MFP) requirements taking shape, and Inflation Reduction Act (IRA) provisions already impacting revenue models, pharmaceutical manufacturers face a gauntlet of regulatory checkpoints before, during, and after… Read More
How 2025 Is Changing Sunshine Act Compliance: What Life Sciences Companies Need to Know
The Sunshine Act landscape is shifting rapidly in 2025, bringing new challenges and opportunities for life sciences companies. Increased regulatory scrutiny, evolving audit protocols, and the rise of advanced technologies, such as artificial intelligence (AI), are reshaping how organizations approach compliance. Here’s what your business needs to know to stay… Read More
iCoach Coaching Tip: 7 Tips to Providing Difficult Feedback to Reluctant Employees
Providing constructive feedback is often as challenging to deliver as it is to receive, particularly when employees react with strong emotions such as anger, tears, or denial. To facilitate smoother and more productive conversations, consider implementing the following detailed steps: 1. Don’t Save It Up:… Read More
Live Webinar: Modernizing Customer Class of Trade Management: Best Practices for Clean Segmentation & Contracting
Join us for a live webinar hosted by Sarah McClure, VP of Knowledge Management Date: July 15, 2025 Time: 2:00 PM ET Special Guests: To be announced! Why Attend? Channel complexity is increasing- IDNs, specialty pharmacies, and 340B entities are reshaping the landscape. Getting your Class of Trade… Read More
President Trump Unveils Sweeping “Most Favored Nation” Drug Pricing Policy
On May 12, 2025, President Donald Trump announced a bold new policy proposal aimed at tackling one of the most persistent issues in American healthcare: the high cost of prescription drugs. The centerpiece of this announcement is the introduction of a “most favored nation” (MFN) model, a strategy that would… Read More